Document is current

Article History

Received: 10 September 2024

Accepted: 12 September 2024

First Online: 27 October 2024

Conflict of interest

: S. Arasi declares that she has participated as an advisory board member and/or consultant, and/or speaker/chair at scientific meetings for Aimmune, DBV, Ferrero, Mabylon, Novartis, Stallergenes Greer, and Ulrich outside the submitted work. L. Klimek has received research grants from Allergy Therapeutics/Bencard, Great Britain/Germany; ALK-Abelló, Denmark; Allergopharma, Germany; Aimmune, USA; ASIT Biotech, Belgium; AstraZeneca, Sweden, Bionorica, Germany; BioNTech, Germany, Biomay, Austria, Boehringer Ingelheim, Germany, Circassia, USA; Chiesi, Italy; Cytos, Switzerland; Curalogic, Denmark; HAL, Netherlands; Lofarma, Italy; Menarini, Italy; Viatris/Mylan, USA; Novartis, Switzerland, Leti, Spain; ROXALL, Germany; GlaxoSmithKline (GSK), Great Britain; Sanofi, France; Stallergenes, France; Thermofisher, USA and/or has served on the speaker’s bureau or was consulting for the aforementioned pharmaceutical companies. LK is the current President of the German Society of Allergology AeDA, Governance Committee Board Member and ROC ENT Chair of the European Academy for Allergy and Clinical Immunology (EAACI), Vice-President of German Academy for Allergy and Environmental Medicine and Editor-in-Chief of <i>AllergoJournal</i> and <i>AllergoJournal International</i>. L. Lo Scalzo, M. Sciannamea, A. Cafarotti and L. Dahdah declare that they have no competing interests.